首页> 美国卫生研究院文献>Parasite Epidemiology and Control >Current status and future prospects of protein vaccine candidates against Schistosoma mansoni infection
【2h】

Current status and future prospects of protein vaccine candidates against Schistosoma mansoni infection

机译:蛋白质疫苗候选对抗血吸虫麦森感染的现状和未来前景

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Schistosomiasis is an acute and chronic tropical parasitic disease caused by blood dwelling worm of the genus Schistosoma. It is the most destructive disease globally and is a major cause of morbidity and mortality for developing countries. Three main species of schistosomes infect human beings from which S. mansoni is the most common and widespread. Over the last several decades, chemotherapy using praziquantel has been a commonly used strategy for the treatment and control of schistosomiasis. However, control programs focused exclusively on chemotherapy have been challenging because of the frequency and rapidity of reinfection and these programs were expensive. Thus, new schistosomiasis control strategies will be needed.
机译:血吸虫病是由血吸虫属的血液住宅蠕虫引起的急性和慢性热带寄生疾病。全球最具破坏性的疾病,是发展中国家发病率和死亡率的主要原因。三种主要物种的血吸虫感染了人类,从中是曼森人是最常见和广泛的。在过去的几十年中,使用Praziquantel的化疗是一种常用的血吸虫病治疗和控制的策略。然而,由于重新感染的频率和速度,因此专注于化疗的控制计划一直在具有挑战性,并且这些节目昂贵。因此,将需要新的血吸虫病控制策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号